SELLAS Life Sciences Group, Inc. — Director's Dealing 2017

Apr 12, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2017-04-10

Reporting Person: Nisi Rudolph (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-04-10	Common Stock	A	10927	$0.59	Acquired	15364	Direct

Footnotes

F1: Effective January 1, 2017, 33% of the cash retainer payment to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter.

F2: Represents the closing stock price of the Company's stock on the first trading day of the quarter.